Page 80 - Read Online

Casolino et al. Hepatoma Res 2021;7:76 https://dx.doi.org/10.20517/2394-5079.2021.79 Page 23 of 23

114. Mertens JC, Fingas CD, Christensen JD, et al. Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma.
Cancer Res 2013;73:897-907. DOI PubMed PMC
115. Ling H, Roux E, Hempel D, et al. Transforming growth factor β neutralization ameliorates pre-existing hepatic fibrosis and reduces
cholangiocarcinoma in thioacetamide-treated rats. PLoS One 2013;8:e54499. DOI PubMed PMC
116. Mehta R, Wood AC, Yu J, Kim R. Investigational PARP inhibitors for the treatment of biliary tract cancer: spotlight on preclinical
and clinical studies. Expert Opin Investig Drugs 2021;30:451-61. DOI PubMed
117. Ahn DH, Bekaii-Saab T. Biliary tract cancer and genomic alterations in homologous recombinant deficiency: exploiting synthetic
lethality with PARP inhibitors. Chin Clin Oncol 2020;9:6. DOI PubMed
118. O'Connor MJ. Targeting the DNA damage response in cancer. Mol Cell 2015;60:547-60. DOI PubMed
119. Golan T, Raitses-Gurevich M, Kelley RK, et al. Overall survival and clinical characteristics of BRCA-associated
cholangiocarcinoma: a multicenter retrospective study. Oncologist 2017;22:804-10. DOI PubMed PMC
120. Sulkowski PL, Corso CD, Robinson ND, et al. 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous
recombination and induces PARP inhibitor sensitivity. Sci Transl Med 2017;9:eaal2463. DOI PubMed PMC
121. Peyraud F, Italiano A. Combined PARP inhibition and immune checkpoint therapy in solid tumors. Cancers (Basel) 2020;12:1502.
DOI PubMed PMC
122. Miyamoto M, Ojima H, Iwasaki M, et al. Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma. Br
J Cancer 2011;105:131-8. DOI PubMed PMC
123. Lyseng-Williamson KA. Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use. Drugs Ther
Perspect 2018;34:457-65. DOI PubMed PMC
124. Goyal L, Zheng H, Yurgelun MB, et al. A phase 2 and biomarker study of cabozantinib in patients with advanced
cholangiocarcinoma. Cancer 2017;123:1979-88. DOI PubMed PMC
125. Zuo M, Rashid A, Churi C, et al. Novel therapeutic strategy targeting the Hedgehog signalling and mTOR pathways in biliary tract
cancer. Br J Cancer 2015;112:1042-51. DOI PubMed PMC
126. Corti F, Nichetti F, Raimondi A, et al. Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: a review of current evidences
and future perspectives. Cancer Treat Rev 2019;72:45-55. DOI PubMed
127. Goeppert B, Konermann C, Schmidt CR, et al. Global alterations of DNA methylation in cholangiocarcinoma target the Wnt
signaling pathway. Hepatology 2014;59:544-54. DOI PubMed
128. O'Rourke CJ, Munoz-Garrido P, Aguayo EL, Andersen JB. Epigenome dysregulation in cholangiocarcinoma. Biochim Biophys Acta
Mol Basis Dis 2018;1864:1423-34. DOI PubMed